Antiangiogenics and radiotherapy

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 8, 2008, Pages 1029-1036

  Shannon, Aoife M ^a   Williams, Kaye J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; BEVACIZUMAB; CEDIRANIB; CYTOKINE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPOXIA INDUCIBLE FACTOR 1; MONOCLONAL ANTIBODY DC101; SEMAXANIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

ANGIOGENESIS; CANCER RADIOTHERAPY; COLORECTAL CANCER; ENDOTHELIUM CELL; GLIOBLASTOMA; HYPOXIA; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NONHUMAN; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 47949131646     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.8.0009     Document Type: Review

References (84)

1. Abdollahi, A., Lipson, K. E., Han, X., Krempien, R., Trinh, T., Weber, K. J., Hahnfeldt, P., Hlatky, L., Debus, J., Howlett, A. R., Huber, P. E. (2003) SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63: 3755-3763
2. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., Millard, P., Fuggle, S., Harris, A. L. (2002) Hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62: 2493-2497
3. Byrne, A. M., Bouchier-Hayes, D. J., Harmey, J. H. (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 9: 777-794
4. Cao, C., Albert, J. M., Geng, L., Ivy, P. S., Sandler, A., Johnson, D. H., Lu, B. (2006) Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 66: 11409-11415
5. Chan, L. W., Camphausen, K. (2003) Angiogenic tumor markers, antiangiogenic agents and radiation therapy. Expert Rev. Anticancer Ther. 3: 357-366
6. Chang, S. M., Lamborn, K. R., Malec, M., Larson, D., Wara, W., Sneed, P., Rabbitt, J., Page, M., Nicholas, M. K., Prados, M. D. (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60: 353-357
7. D'Amato, R. J., Loughnan, M. S., Flynn, E., Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U S A 91: 4082-4085
8. Denekamp, J. (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66: 181-196
9. Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H. W., Chen, R., Muller, G. W., Stirling, D., Dalgleish, A. G. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 87: 1166-1172
10. Dvorak, H. F., Detmar, M., Claffey, K. P., Nagy, J. A., van de Water, L., Senger, D. R. (1995) Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int. Arch. Allergy Immunol. 107: 233-235
11. Ergun, A., Camphausen, K., Wein, L. M. (2003) Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65: 407-424
12. Fenton, B. M., Paoni, S. F., Ding, I. (2004) Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. 64: 5712-5719
13. Fillies, T., Werkmeister, R., van Diest, P. J., Brandt, B., Joos, U., Buerger, H. (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5: 84
14. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285: 1182-1186
15. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., Semenza, G. L. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16: 4604-4613
16. Franco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A. M., Brown, A. S., Hicklin, D. J., Foster, F. S., Kerbel, R. S. (2006) Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66: 3639-3648
17. Galarraga, J., Loreck, D. J., Graham, J. F., DeLaPaz, R. L., Smith, B. H., Hallgren, D., Cummins, C. J. (1986) Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab. Brain Dis. 1: 279-291
18. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., Kolesnick, R. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159
19. Geng, L., Donnelly, E., McMahon, G., Lin, P. C., Sierra-Rivera, E., Oshinka, H., Hallahan, D. E. (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61: 2413-2419
20. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., Weichselbaum, R. R. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59: 3374-3378
21. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., Scott, O. C. (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26: 638-648
22. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., Johnson, R. S. (1999) Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59: 1592-1598
23. Gupta, V. K., Jaskowiak, N. T., Beckett, M. A., Mauceri, H. J., Grunstein, J., Johnson, R. S., Calvin, D. A., Nodzenski, E., Pejovic, M., Kufe, D. W., Posner, M. C., Weichselbaum, R. R. (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 8: 47-54
24. Hanahan, D., Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
25. Harmey, J. H., Bouchier-Hayes, D. (2002) Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 24: 280-283
26. Harris, A. L. (2002) Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2: 38-47
27. Hess, C., Vuong, V., Hegyi, I., Riesterer, O., Wood, J., Fabbro, D., Glanzmann, C., Bodis, S., Pruschy, M. (2001) Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer 85: 2010-2016
28. Höckel, M., Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer. Inst. 93: 266-276
29. Höckel, M., Vorndran, B., Schlenger, K., Baussmann, E., Knapstein, P. G. (1993) Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol. 51: 141-149
30. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl. Acad. Sci. U S A 95: 7987-7992
31. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335-2342
32. Jain, R. K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7: 987-989
33. Jain, R. K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
34. Kerbel, R. S. (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515
35. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., Suit, H. D. (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44
36. Kozin, S. V., Winkler, F., Garkavtsev, I., Hicklin, D. J., Jain, R. K., Boucher, Y. (2007) Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. Cancer Res. 67: 5076-5082
37. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., Livingston, D. M. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6: 1335-1340
38. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., Boucher, Y. (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60: 5565-5570
39. Liu, W., Ahmad, S. A., Reinmuth, N., Shaheen, R. M., Jung, Y. D., Fan, F., Ellis, L. M. (2000) Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323-328
40. Lordick, F., Geinitz, H., Theisen, J., Sendler, A., Sarbia, M. (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int. J. Radiat. Oncol. Biol. Phys. 64: 1295-1298
41. Matter, A. (2001) Tumor angiogenesis as a therapeutic target. Drug Discov. Today 6: 1005-1024
42. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., Weichselbaum, R. R. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291
43. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., Ratcliffe, P. J. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U S A 94: 8104-8109
44. McBride, W. H., Chiang, C. S., Olson, J. L., Wang, C. C., Hong, J. H., Pajonk, F., Dougherty, G. J., Iwamoto, K. S., Pervan, M., Liao, Y. P. (2004) A sense of danger from radiation. Radiat. Res. 162: 1-19
45. McCarty, M. F., Liu, W., Fan, F., Parikh, A., Reimuth, N., Stoeltzing, O., Ellis, L. M. (2003) Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol. Med. 9: 53-58
46. McDonnell, C. O., Bouchier-Hayes, D. J., Toomey, D., Foley, D., Kay, E. W., Leen, E., Walsh, T. N. (2003) Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. Br. J. Surg. 90: 1373-1378
47. Moeller, B. J., Cao, Y., Li, C. Y., Dewhirst, M. W. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441
48. Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., Dewhirst, M. W. (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8: 99-110
49. Murata, R., Nishimura, Y., Hiraoka, M. (1997) An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37: 1107-1113
50. Ning, S., Laird, D., Cherrington, J. M., Knox, S. J. (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157: 45-51
51. O'Donnell, J. L., Joyce, M. R., Shannon, A. M., Harmey, J., Geraghty, J., Bouchier-Hayes, D. (2006) Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat. Rev. 32: 407-416
52. Okunieff, P., Hoeckel, M., Dunphy, E. P., Schlenger, K., Knoop, C., Vaupel, P. (1993) Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int. J. Radiat. Oncol. Biol. Phys. 26: 631-636
53. Park, J. S., Qiao, L., Su, Z. Z., Hinman, D., Willoughby, K., McKinstry, R., Yacoub, A., Duigou, G. J., Young, C. S., Grant, S., Hagan, M. P., Ellis, E., Fisher, P. B., Dent, P. (2001) Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20: 3266-3280
54. Quesada, A. R., Munoz-Chapuli, R., Medina, M. A. (2006) Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev. 26: 483-530
55. Raghunand, N., Gatenby, R. A., Gillies, R. J. (2003) Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. 76: S11-S22
56. Riesterer, O., Honer, M., Jochum, W., Oehler, C., Ametamey, S., Pruschy, M. (2006) Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin. Cancer Res. 12: 3518-3524
57. Ryan, H. E., Lo, J., Johnson, R. S. (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17: 3005-3015
58. Schueneman, A. J., Himmelfarb, E., Geng, L., Tan, J., Donnelly, E., Mendel, D., McMahon, G., Hallahan, D. E. (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63: 4009-4016
59. Semenza, G. L. (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88: 1474-1480
60. Semenza, G. L. (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8: S62-S67
61. Semenza, G. L., Nejfelt, M. K., Chi, S. M., Antonarakis, S. E. (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. U S A 88: 5680-5684
62. Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., Toomey, D. (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29: 297-307
63. Shih, S. C., Claffey, K. P. (1998) Hypoxia-mediated regulation of gene expression in mammalian cells. Int. J. Exp. Pathol. 79: 347-357
64. Shweiki, D., Itin, A., Softer, D., Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
65. Solesvik, O. V., Rofstad, E. K., Brustad, T. (1984) Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat. Res. 98: 115-128
66. Sonveaux, P., Brouet, A., Havaux, X., Gregoire, V., Dessy, C., Balligand, J. L., Feron, O. (2003) Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res. 63: 1012-1019
67. Steel, G. (1997) (ed.) The role of radiotherapy in the management of cancer. Edward Arnold, London
68. Sutherland, R. M. (1998) Tumor hypoxia and gene expression - implications for malignant progression and therapy. Acta Oncol. 37: 567-574
69. Teicher, B. A., Sotomayor, E. A., Huang, Z. D. (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52: 6702-6704
70. Teicher, B. A., Holden, S. A., Ara, G., Dupuis, N. P., Liu, F., Yuan, J., Ikebe, M., Kakeji, Y. (1995) Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int. J. Cancer 61: 732-737
71. Vaupel, P., Kallinowski, F., Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49: 6449-6465
72. Vaupel, P., Kelleher, D. K., Höckel, M. (2001a) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28: 29-35
73. Vaupel, P., Thews, O., Hoeckel, M. (2001b) Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18: 243-259
74. Wachsberger, P., Burd, R., Dicker, A. P. (2004) Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol. Oncol. Clin. North Am. 18: 1039-1057, viii
75. 2 tension. Proc. Natl. Acad. Sci. U S A 92: 5510-5514
76. Warburg, O. (1956) On the origin of cancer cells. Science 123: 309-314
77. Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., Chester, R., Jackson, J. A., Boffey, S. J., Kilburn, L. L., Barnett, S., Richmond, G. H., Wadsworth, P. F., Walker, M., Bigley, A. L., Taylor, S. T., Cooper, L., Beck, S., Jurgensmeier, J. M., Ogilvie, D. J. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65: 4389-4400
78. Williams, K. J., Telfer, B. A., Brave, S., Kendrew, J., Whittaker, L., Stratford, I. J., Wedge, S. R. (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10: 8587-8593
79. Williams, K. J., Telfer, B. A., Xenaki, D., Sheridan, M. R., Desbaillets, I., Peters, H. J., Honess, D., Harris, A. L., Dachs, G. U., van der Kogel, A., Stratford, I. J. (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75: 89-98
80. Williams, K. J., Telfer, B. A., ShannoN, A. M., Babur, M., Stratford, I. J., Wedge, S. R. (2007) Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol. Cancer Ther. 6: 599-606
81. Winkler, F., Kozin, S. V., Tong, R. T., Chae, S. S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., Munn, L. L., Jain, R. K. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563
82. Zips, D., Krause, M., Hessel, F., Westphal, J., Bruchner, K., Eicheler, W., Dorfler, A., Grenman, R., Petersen, C., Haberey, M., Baumann, M. (2003) Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 23: 3869-3876
83. Zips, D., Eicheler, W., Geyer, P., Hessel, F., Dorfler, A., Thames, H. D., Haberey, M., Baumann, M. (2005) Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 65: 5374-5379
84. Zywietz, F., Hahn, L. S., Lierse, W. (1994) Ultrastructural studies on tumor capillaries of a rat rhabdomyosarcoma during fractionated radiotherapy. Acta Anal (Basel) 150: 80-85